Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of “Hold” from Analysts

Share on StockTwits

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned an average recommendation of “Hold” from the eight research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $20.75.

Several brokerages recently issued reports on HALO. Barclays restated a “sell” rating and issued a $17.00 target price on shares of Halozyme Therapeutics in a report on Monday, August 12th. ValuEngine upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, June 27th. Zacks Investment Research upgraded shares of Halozyme Therapeutics from a “sell” rating to a “hold” rating and set a $18.00 price target on the stock in a report on Wednesday, August 7th. Cantor Fitzgerald lifted their price target on shares of Halozyme Therapeutics from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, July 1st. Finally, BidaskClub upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtus ETF Advisers LLC grew its stake in shares of Halozyme Therapeutics by 1.2% in the 2nd quarter. Virtus ETF Advisers LLC now owns 51,461 shares of the biopharmaceutical company’s stock worth $884,000 after buying an additional 626 shares in the last quarter. Taylor Wealth Management Partners boosted its stake in shares of Halozyme Therapeutics by 0.4% during the 2nd quarter. Taylor Wealth Management Partners now owns 205,084 shares of the biopharmaceutical company’s stock worth $3,523,000 after purchasing an additional 735 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Halozyme Therapeutics by 25.2% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 967 shares during the period. NumerixS Investment Technologies Inc boosted its stake in shares of Halozyme Therapeutics by 70.7% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 2,390 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 990 shares during the period. Finally, Commonwealth Equity Services LLC boosted its stake in shares of Halozyme Therapeutics by 2.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 44,890 shares of the biopharmaceutical company’s stock worth $771,000 after purchasing an additional 1,050 shares during the period. Institutional investors own 79.98% of the company’s stock.

Shares of HALO stock opened at $16.48 on Friday. Halozyme Therapeutics has a 12-month low of $13.24 and a 12-month high of $18.85. The company has a current ratio of 2.89, a quick ratio of 2.57 and a debt-to-equity ratio of 0.05. The firm’s 50 day moving average is $16.67 and its 200 day moving average is $16.38. The stock has a market capitalization of $2.41 billion, a P/E ratio of -29.43 and a beta of 1.76.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. Halozyme Therapeutics had a negative net margin of 23.53% and a negative return on equity of 16.97%. The company had revenue of $39.10 million for the quarter, compared to analysts’ expectations of $42.94 million. During the same quarter last year, the company posted ($0.16) earnings per share. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. As a group, equities analysts predict that Halozyme Therapeutics will post -0.35 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.

Featured Article: What is the Rule of 72?

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Swiss National Bank Buys 4,900 Shares of ChannelAdvisor Corp
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 960 Shares of AT&T Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
Doheny Asset Management CA Buys 2,865 Shares of Xilinx, Inc.
$1.31 EPS Expected for Microchip Technology Inc.  This Quarter
$1.31 EPS Expected for Microchip Technology Inc. This Quarter
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
Doheny Asset Management CA Has $387,000 Stock Holdings in Lowe’s Companies, Inc.
-$0.63 Earnings Per Share Expected for Instructure Inc  This Quarter
-$0.63 Earnings Per Share Expected for Instructure Inc This Quarter


© 2006-2019 Ticker Report